RGMa-Inhibiting Therapy for Advanced HAM Neuronal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HTLV-1-associated myelopathy (HAM) using anti-CCR4 antibodies have limited effectiveness on patients with advanced neuronal destruction, necessitating a more effective therapeutic approach.
Innovation Solution
The use of antibodies that inhibit RGMa activity or expression, such as siRNA, shRNA, antisense oligonucleotides, and anti-RGMa antibodies, to target and reduce RGMa function in HTLV-1-infected cells, thereby mitigating inflammation and neuronal cell death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CCR4 antibody treatment is used, then symptoms of HAM are improved by decreasing HTLV-1-infected cells and reducing spinal cord inflammation, but the treatment has limited effect on patients with advanced neuronal destruction
Solution Approach 1:
The patent changes the therapeutic target from CCR4 (chemokine receptor) to RGMa (repulsive guidance molecule), representing a fundamental parameter change in the treatment approach. This switch enables the treatment to address not only inflammation but also neuronal destruction and regeneration, making it effective for advanced stages of HAM where anti-CCR4 therapy fails
2Ease of operation
If symptomatic therapy is practiced, then quality of life is maintained temporarily, but no effective method for treating HAM has been established and disease progression cannot be halted
Solution Approach 1:
The patent replaces the symptomatic management approach (mechanical support and symptom control) with a disease-modifying therapeutic mechanism that targets the underlying pathogenic processes. By using anti-RGMa antibodies to block the molecular mechanisms driving neuronal destruction and inflammation, the treatment transitions from merely managing symptoms to actively modifying the disease course and preventing progression
3Reliability
If RGMa-inhibiting substances are used, then neuronal regeneration and regrowth of disrupted neuronal connection is promoted, but the mechanism involves complex interactions with neogenin and BMP-2/4 signaling
Solution Approach 1:
The patent uses anti-RGMa antibodies as intermediary molecules that block the interaction between RGMa and its receptor neogenin. This intermediary approach simplifies the complex molecular network by targeting a single key node (RGMa-neogenin interaction) that controls downstream signaling pathways involving BMP-2/4, thereby promoting neuronal regeneration without needing to directly manipulate multiple complex interactions
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
The present invention provides a therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), comprising an RGMa-inhibiting substance, and a method for treating HTLV-1-associated myelopathy (HAM), comprising administering a pharmacologically effective amount of an RGMa-inhibiting substance to an HAM patient in need thereof.